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Summary
Background: There is an apparent link between thrombogenesis and inﬂammation. We
hypothesized that systemic inﬂammation [as indicated by C-reactive protein (CRP)] would be
related to the presence of left atrial (LA) thrombus in patients with atrial ﬁbrillation (AF). To
test this hypothesis, we evaluated the relationship between CRP and LA thrombus in patients
with non-rheumatic AF.
Methods and results: Between October 2004 and December 2008, 190 patients with non-
rheumatic AF (122 males, age 71± 10 years) who underwent transesophageal echocardiography
(TEE) were enrolled and analyzed. All patients were examined for presence or absence of LA
thrombus by TEE. CRP was measured within 1 week before the TEE examination. LA thrombus
was detected in 19 patients (10%). Hypertension, hypertensive heart disease (HHD), valvular
heart disease, ticlopidine, and CRP were univariate correlates of LA thrombus. By multivariate
analysis, HHD (p < 0.01), ticlopidine (p = 0.01), and CRP (p = 0.03) were independently associated
with LA thrombus. A cut-off CRP value for identifying LA thrombus was 0.21mg/dl (sensitivity:
84%, speciﬁcity: 60%, positive predictive value: 19%, and negative predictive value: 97%).
late
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ntroduction
trial ﬁbrillation (AF) is a common arrhythmia that repre-
ents an independent risk factor for systemic as well as cere-
ral embolism [1]. Abnormalities of hemostasis, ﬁbrinolysis,
ndothelium, and platelet function in AF may increase the
isk of stroke and thromboembolism [2,3]. These prothrom-
otic states in addition to left atrial (LA) blood stasis may be
Published by Elsevier Ireland Ltd. All rights reserved.
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5Inﬂammation and left atrial thrombus
associated with LA thrombus and spontaneous echo contrast
(SEC) [3]. Transesophageal echocardiography (TEE) has been
widely and reliably used to detect LA thrombus and SEC with
high accuracy [4—6].On the other hand, there is an apparent
link between thrombogenesis and inﬂammation [7—10]. We
hypothesized that systemic inﬂammation [as indicated by C-
reactive protein (CRP)] would be related to the presence of
LA thrombus in patients with AF. To test this hypothesis, we
evaluated the relationship between CRP and LA thrombus in
patients with non-rheumatic AF.
Methods
Study patients
The study population was identiﬁed from a retrospective
database of 278 consecutive patients with AF who under-
went TEE from October 2004 to December 2008. Patients
with rheumatic valvular heart diseases (n = 13), prosthetic
valve after operation of mitral stenosis (n = 11), and those in
whom only the aorta was observed because of aortic dissec-
tion (n = 2) were excluded from this study. In 29 cases with
multiple TEE examinations (total 88), only the ﬁrst exam-
ination was included in this study. Finally, a total of 190
patients (122 males, 68 females, mean age 71± 10 years,
range 36—95 years) with AF were enrolled and analyzed.
Among these patients, 6 patients had infective endocardi-
tis, 3 patients had aortic dissection, 24 patients had recent
embolic events that occurred within 2 weeks (including
acute ischemic stroke).
According to the TEE result, the study patients were
divided into 2 groups depending on the presence (n = 19) or
absence (n = 171) of LA thrombus. In patients with LA throm-
bus, 10 patients had recent embolic events that occurred
within 2 weeks (including acute ischemic stroke).
In addition, patients treated with warfarin therapy [the
target prothrombin time-international normalized ratio (PT-
INR) value of between 2.0 and 3.0 for patients aged < 70
years or PT-INR value of between 1.6 and 2.6 for patients
aged≥ 70 years] [11,12] for more than 3 weeks at the time
of TEE (n = 73, 38.4%) were also divided into 2 groups, with
(n = 8, 11.0%) and without (n = 65, 89.0%) LA thrombus.
Transthoracic echocardiography (TTE)
All echocardiographic examinations were performed by
using Sonos 7500 (Philips Ultrasound, Bothell, WA, USA) with
an S3 probe. All subjects underwent a standard transthoracic
2 dimensional (2D) and Doppler echocardiographic examina-
tions. In addition to routine conventional echocardiographic
indices, we measured LA volume. LA volume was measured
by the prolate-ellipsoid method, LA volume was calculated
as reported previously [13—15].
Transesophageal echocardiographyA T6H probe was used for 2D TEE images by using Sonos 7500
(Philips Ultrasound). In TEE, the following features were
speciﬁcally assessed: (1) presence or absence of thrombus
in the LA or LA appendage (LAA); (2) presence or absence
<
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f SEC within the LA or LAA; (3) peak emptying velocity of
he LAA; (4) presence or absence of signiﬁcant (≥ moderate)
itral regurgitation (MR).
Thrombus were deﬁned as highly echogenic masses adja-
ent to the endocardial surface and clearly differentiated
rom normal structures such as the pectinate muscles. SEC
as deﬁned as slowly swirling, smoke-like echoes inside the
A or LAA. Gain was continuously adjusted to ensure good
isualization and to avoid noise artifacts. The LAA peak emp-
ying velocity was obtained by Doppler echocardiography.
wo experienced cardiologists interpreted the TEE blinded
o the laboratory data.
ata collection
n each patient, the following information had been col-
ected as the initial clinical parameters: gender, age, body
ass index (BMI), type of antithrombotic therapy (war-
arin, heparin, aspirin, or ticlopidine), coexisting conditions
ncluding valvular heart disease which includes signiﬁcant
R, aortic valve regurgitation and aortic valve steno-
is, ischemic heart disease, hypertrophic cardiomyopathy,
ilated cardiomyopathy, hypertensive heart disease (HHD),
ongenital heart disease, hypertension, diabetes mellitus,
nd hyperlipidemia. Lone AF was deﬁned as AF occurring
n the absence of structural heart disease and hypertension
nder the age of 65 years.
lood samples
lood samples were taken within 1 week before the TEE
xamination. In our hospital, laboratory data including
RP were measured routinely before TEE examination. The
erum CRP was measured by latex nephelometry (LT Auto
ako CRP, Osaka, Japan). We used latex as the reagent and
itachi 7500 analyzer (Hitachi, Tokyo, Japan) as the mea-
urement system. The lowest detection CRP limit of this test
as <0.02mg/dl. After blood samples were taken, medica-
ions including anticoagulation were not changed until TEE
xamination was performed.
tatistical analysis
ata are expressed as mean value± SD or as median value
ith interquartile range. Differences in clinical features
nd plasma markers between patients with and without LA
hrombus were evaluated with an unpaired Student t-test for
ormally distributed continuous variables, Mann—Whitney
-test for nonparametrically distributed continuous vari-
bles, and chi-square tests for categorical variables. Factors
igniﬁcantly associated with LA thrombus on univariate
nalysis (p < 0.05) were entered into a stepwise logistic
egression analysis to determine independent associates of
A thrombus. Statistical analyses were done with StatView
.0 software (SAS Institute, Cary, NC, USA). A p-value of
0.05 was considered statistically signiﬁcant. Inter- and
ntra-observer agreements for the detection of LA throm-
us was assessed by using kappa statistics. A kappa index
bove 0.8 was considered to indicate very good agree-
ent.
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Table 1 Clinical characteristics and research indices in patients with and without left atrial (LA) thrombus.
LA thrombus (−) LA thrombus (+) p
N 171 19
Age (years) 70.9± 9.8 75.4± 10.1 0.06
Male (%) 63.7 68.4 0.69
Body mass index (kg/m2) 22.8± 3.5 22.5± 3.2 0.68
Smoker (%) 36.8 34.5 0.84
Diabetes mellitus (%) 22.2 42.1 0.09
Hypertension (%) 62.0 89.5 0.02
Hyperlipidemia (%) 22.2 42.1 0.09
ACEI/ARB (%) 33.9 47.4 0.24
Warfarin (≥21 days) (%) 9.4 11.0 0.73
Aspirin (%) 22.8 36.8 0.26
Ticlopidine (%) 3.5 21.1 0.01
Statin (%) 18.1 31.6 0.22
Ischemic heart disease (%) 10.5 15.8 0.45
Dilated cardiomyopathy (%) 2.3 0.0 1.00
Hypertrophic cardiomyopathy (%) 6.4 5.3 1.00
Hypertensive heart disease (%) 16.4 63.2 <0.01
Congenital heart disease (%) 3.5 0.0 1.00
Valvular heart disease (%) 45.0 21.1 0.04
Lone atrial ﬁbrillation (%) 2.9 0.0 1.00
White blood cells (/l) 6225± 2195 7824± 4041 0.05
Red blood cells (×104/l) 417± 622 447± 75 0.05
Hematocrit (%) 39.8± 7.5 41.9± 5.8 0.08
Platelet (×104/l) 20.0± 5.6 20.1± 6.1 0.72
PT-INR 1.7± 0.8 1.7± 0.6 0.46
APTT (s) 36.2± 14.7 34.8± 12.3 0.64
Creatinine (mg/dl) 0.93± 0.50 0.98± 0.27 0.11
C-reactive protein (mg/dl) 0.13 (0.05—0.72) 0.90 (0.33—2.72) <0.01
Total-cholesterol (mg/dl) 182.4± 42.0 196.6± 59.2 0.65
Triglycerides (mg/dl) 105.7± 60.5 104.9± 67.3 0.57
LDL-cholesterol (mg/dl) 109.5± 33.5 117.9± 50.3 0.52
HDL-cholesterol (mg/dl) 48.6± 15.8 49.2± 16.3 0.95
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operating characteristic (ROC) analysis, a cut-off CRP value
for identifying LA thrombus was 0.21mg/dl (sensitivity: 84%,
speciﬁcity: 60%, positive predictive value: 19%, and negative
predictive value: 97%) (Fig. 2).Values are mean± SD, median (interquartile range), or percenta
II receptor blocker; PT-INR, prothrombin time-international norm
lipoprotein; HDL, high density lipoprotein.
esults
A thrombus was detected in 19 of 190 patients (10%).
able 1 summarizes the clinical characteristics of patients
ith and without LA thrombus. There were signiﬁcant dif-
erences in HT, ticlopidine, HHD, valvular heart disease,
nd CRP between the 2 groups. Duration and intensity [PT-
NR and activated partial thromboplastin time (APTT)] of
nticoagulation therapy were not different between the 2
roups.
Fig. 1 shows a box plot of CRP in patients with and without
A thrombus. CRP in patients with LA thrombus was signif-
cantly higher than in patients without LA thrombus [0.90
0.33—2.72) vs. 0.13 (0.05—0.72) mg/dl, p < 0.01].
Table 2 shows the TTE and TEE ﬁndings. There were signif-
cant differences in LA dimension, intraventricular septum,
nd posterior wall thickness between the 2 groups. In addi-
ion, in patients with LA thrombus, the LAA velocity was
igniﬁcantly lower and signiﬁcant MR was less frequently
bserved than in patients without LA thrombus. In this study,
EC was found in all patients with LA thrombus. The kappa
tatistic for inter- and intra-observer agreements for LA
hrombus by TEE were 0.94 and 1.00, respectively.
By multivariate analysis, HHD (p < 0.01), ticlopidine
p = 0.01), and CRP (p = 0.03) were independent clinical pre-
F
pCEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin
d; APTT, activated partial thromboplastin time; LDL, low density
ictors of LA thrombus (Table 3). According to the receiverigure 1 Comparison of C-reactive protein (CRP) between
atients with and without left atrial (LA) thrombus.
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Table 2 Findings on transthoracic echocardiography and transesophageal echocardiography.
LA thrombus (−) LA thrombus (+) p
TTE ﬁndings
LA dimension (cm) 4.5± 0.8 4.8± 0.9 0.04
LA volume (ml) 70.7± 58.1 70.9± 36.7 0.53
E prime (cm/s) 7.0± 2.5 6.8± 1.1 0.58
Intra ventricular septum (cm) 1.1± 0.2 1.4± 0.4 <0.01
Posterior wall (cm) 1.1± 0.2 1.3± 0.3 <0.01
LVDd (cm) 4.7± 0.8 4.6± 0.9 0.63
LVDs (cm) 3.2± 0.9 3.1± 1.2 0.39
Ejection fraction (%) 57.4± 12.2 54.2± 15.4 0.56
TEE ﬁndings
Spontaneous echo contrast (%) 26.9 100.0 <0.01
LAA velocity (cm/s) 36.7± 21.0 18.3± 5.9 <0.01
Signiﬁcant MR (%) 33.7 10.5 0.04
LA, left atrium; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; LVDd, left ventricular diastolic dimension;
LVDs, left ventricular systolic dimension; LAA, left atrial appendage; MR, mitral regurgitation.
Table 3 Multivariate analysis of characteristics and C-reactive protein levels.
Odds ratio (95% CI) p
Hypertensive heart disease 7.855 (2.513—24.554) <0.01
C-reactive protein 1.215 (1.025—1.439) 0.025
Ticlopidine 7.214 (1.537—33.869) 0.012
pSigniﬁcant mitral regurgitation
Valvular heart disease
Among the patients who were receiving warfarin therapy
at the time of TEE (n = 77), CRP was also signiﬁcantly higher
in patients with LA thrombus [n = 8, 0.98 (0.67—1.45) vs. 0.11
(0.04—0.36) mg/dl, p < 0.01] (Fig. 3) despite similar INR val-
ues between the two groups (2.02± 0.71 vs. 2.09± 0.78,
Figure 2 Receiver operating characteristics curve to deter-
mine the cut-off value of C-reactive protein for left atrial
thrombus detection by transesophageal echocardiography.
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t0.605 (0.063—5.822) 0.663
0.667 (0.107—4.164) 0.664
= 0.92). Optimal anticoagulation (deﬁned as PT-INR value
f between 2.0 and 3.0 for patients aged < 70 years or PT-INR
alue of between 1.6 and 2.6 for patients aged≥ 70 years)
11,12] was not achieved in 19 patients (25%), 3 (16%) in
atients with LA thrombus and 16 (9%) in patients without
A thrombus.
According to the ROC analysis, a cut-off CRP value
or identifying LA thrombus in patients receiving warfarin
herapy was 0.62mg/dl (sensitivity: 88%, speciﬁcity: 81%,
igure 3 Comparison of C-reactive protein (CRP) between
arfarin-treated patients with and without left atrial (LA)
hrombus.
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ositive predictive value: 35%, and negative predictive
alue: 98%).
On the other hand, among the patients who were receiv-
ng heparin therapy (n = 70, 36.8%), LA thrombus was found
n 10 patients. CRP showed a trend toward being higher
n patients with LA thrombus than those without [0.78
0.26—4.81) vs. 0.17 (0.08—0.53) mg/dl, p = 0.03] despite
imilar APTT values between the two groups (38.4± 14.7
s. 38.0± 15.6 s, p = 0.82).
Repeated TEE examinations were performed in 10 of 19
atients (53%) with LA thrombus. LA thrombus resolved in
patients, whereas LA thrombus persisted in the remain-
ng 6 patients. The baseline CRP at the time of the ﬁrst
EE was comparable between patients whose LA thrombus
isappeared and remained. During follow-up, CRP showed
trend toward decrease in both groups [resolved group:
.47 (0.15—1.06) to 0.20 (0.04—0.36) mg/dl, p = 0.28, per-
isted group: 1.24 (0.61—4.26) to 0.77 (0.25—1.24) mg/dl,
= 0.25]. On the other hand, PT-INR signiﬁcantly increased
n patients with resolved LA thrombus (1.51± 0.34 vs.
.63± 0.80, p = 0.03), but not in patients with persistent LA
hrombus (1.92± 0.80 vs. 2.26± 0.73, p = 0.48).
Twenty-nine (15%) of 190 patients had evidence of inﬂam-
atory diseases that could explain a higher CRP. Fourteen
atients had infectious diseases (infective endocarditis,
neumonia, sepsis, and infectious arthritis) and 15 patients
ad other systemic inﬂammatory diseases (rheumatoid
rthritis, hyperthyroidism, aortitis, glomerulonephritis, car-
inoma, and appendicitis). After excluding these patients,
RP was still signiﬁcantly higher in patients with LA throm-
us than in patients without LA thrombus [0.65 (0.26—1.12)
s. 0.12 (0.04—0.42) mg/dl, p < 0.01].
iscussion
o the best of our knowledge, this is the ﬁrst study demon-
trating the relationship between systemic inﬂammation
nd LA thrombus in patients with non-rheumatic AF. The
redilection of LA thrombus formation in AF patients has
ong been known. However, the pathogenesis of auricular
hrombosis has not been entirely speciﬁed yet. Virchow
dentiﬁed a triad of components implicated in the process
f thrombosis [16]: abnormal conditions of blood ﬂow,
essel wall damage, and abnormal blood constituents. In
F, there are variable relations to these three compo-
ents: (1) LAA velocity; (2) atrial endothelial cells; and
3) prothrombotic state. Previous studies have suggested
n association between decreased blood ﬂow in the LAA
s demonstrated by reduced LAA ﬂow velocities and the
oss of atrial contraction in AF [17,18]. Also, the presence
f SEC was related to reduced blood ﬂow velocity in the
AA [19] and could be an independent predictor of LA
hrombus [20,21]. Furthermore, previous studies have
emonstrated that SEC was a predictor of thromboembolic
vents in future [20,22]. The CHADS2 [Congestive heart
ailure, Hypertension, Age, Diabetes, Stroke (Doubled)]
core is widely used as a simple and reliable clinical score
o identify those with high likelihood of ischemic stroke
mong patients with AF [23]. In fact, HHD was indepen-
ently associated with LA thrombus in our present study
opulation. Although previous studies have suggested that
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A thrombus was more frequently found in patients with
ow left ventricular (LV) ejection fraction [24,25], our data
id not support these previous reports, possibly because of
mall sample size. Our study population mainly consisted of
atients with preserved LV systolic function and therefore
id not show impact of LV systolic function on LA thrombus
ormation.
In our present study, incidence of signiﬁcant MR in the
A thrombus group was signiﬁcantly lower than in patients
ithout LA thrombus, concordant with previous reports. Pre-
ious studies suggested that signiﬁcant MR may be protective
gainst the formation of SEC/LA thrombus [26,27].
A signiﬁcant difference was present between LA throm-
us and ticlopidine. This was an unlikely ﬁnding that may
ave been due to chance alone, considering the small num-
er of patients who were on ticlopidine.
Several studies demonstrate that patients with AF show
igniﬁcant increases in plasma ﬁbrinogen and D-dimer levels,
uggesting the presence of a hypercoagulable or pro-
hrombotic state [28—31]. In this study, plasma D-dimer
evel was measured only in 70 patients (37%) at the time
f TEE. Plasma D-dimer levels were signiﬁcantly higher in
atients with LA thrombus than in those without LA throm-
us [2.20 (1.20—8.15) vs. 0.50 (0.50—1.50)g/ml, p < 0.01].
In addition, a previous study has demonstrated that there
s a possible link between CRP and deep vein thrombosis
32]. Therefore, CRP may play some role in LA throm-
us formation. Furthermore, CRP has been suggested as a
iomarker to predict cardiovascular events in apparently
ealthy subjects as well as patients with coronary artery dis-
ase or valvular heart disease [33,34]. However, the exact
echanisms by which CRP affects cardiovascular disease are
till poorly understood and controversial.
In the present study, we found that elevated CRP was
ndependently associated with the presence of LA thrombus.
ur ﬁndings are consistent with those of previous studies
eporting associations between inﬂammation and coagula-
ion [35,36]. It has been reported that CRP promotes platelet
dhesion to endothelial cells and emphasize the possible
ole of CRP in linking inﬂammation and thrombosis and
rovide a potential mechanism for the high incidence of
ascular events associated with high CRP level [37]. Fur-
hermore, a recent report from the Stroke Prevention in
trial Fibrillation (SPAF)-III study demonstrated that CRP was
ositively correlated to stroke risk and related to stroke
isk factors and prognosis in 880 patients with AF [38]. Our
resent results may explain the possible link between stroke
isk and systemic inﬂammation in patients with AF.
An epidemiological study as well as a large-scale ran-
omized trial consistently demonstrated that the incidence
f stroke in patients with AF is related to the size of the
A [39,40]. Morphologic changes of the LA endocardial mus-
le have also been demonstrated in patients with AF [41].
s mentioned, endothelial cells are known to modulate
hrombogenesis [39]. Therefore, it is possible that some pro-
hrombotic alterations in the endocardium may occur during
he process of structural remodeling in the LA wall. Yaron
t al. have shown that CRP directly affected the endothelial
henotype promoting thrombosis [37]. Therefore, in addi-
ion to the impact of the LA enlargement, CRP may modulate
A endothelial function leading to thrombogenic status in
atients with AF.
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Acute embolic events may also be related to elevated
CRP levels. In this study, 24 (13%) of 190 patients had recent
embolic events that occurred within 2 weeks. Among these
patients, 10 had LA thrombus. After excluding these patients
with recent embolic events, CRP was still signiﬁcantly higher
in patients with LA thrombus than in patients without LA
thrombus [0.90 (0.50—1.24) vs. 0.13 (0.05—0.49)mg/dl,
p < 0.01].
The efﬁcacy of oral anticoagulant therapy in reducing
the risk of thromboembolic events has been demonstrated
in patients with AF. To optimize the intensity of anticoagula-
tion, as indicated by the INR, a target INR needs to achieve
the best balance between the prevention of thromboem-
bolic events and the occurrence of bleeding complications
[42—44]. Interestingly, among our study patients on war-
farin, INR value did not differ between patients with and
without LA thrombus. In fact, there were some cases with
LA thrombus even under an acceptable INR value as recom-
mended by guidelines. In addition, there was no correlation
between CRP and INR (r = 0.16, p = 0.73). Therefore, inﬂam-
mation may be related to LA thrombus independent of
anticoagulation states. A multicenter, prospective and ran-
domized study from Japan demonstrated that low intensity
warfarin treatment (INR 1.5—2.1) for prevention of stroke
recurrence was safer than conventional intensity treatment
(INR 2.2—3.5) in the elderly [11]. Yasaka et al. demon-
strated a sharp rise in the incidence of severe hemorrhage in
INR≥ 2.6 and reported that most patients suffering severe
hemorrhage were elderly [12]. Therefore, an INR value
of between 1.6 and 2.6 seems optimal to prevent major
ischemic or hemorrhagic events in elderly Japanese non-
valvular AF patients. However, we found that, some cases,
even if they had maintenance of the INR within the range
which guidelines recommended, had complicated LA throm-
bus. In such cases, CRP levels were signiﬁcantly higher
than in those without LA thrombus. Therefore, presence of
inﬂammation as evident by high CRP level may also help
stratify high-risk patients for LA thrombus formation and
possibly stroke and peripheral embolism in non-rheumatic
AF. In this study, we identiﬁed the cut-off CRP value for
identifying LA thrombus as 0.21mg/dl. In patients receiv-
ing warfarin therapy, the cut-off CRP value was 0.62mg/dl.
Based on our results, the INR value alone may not be enough
to predict LA thrombus formation among patients with high
CRP. Although LA thrombus resolved in 4 of 10 patients who
underwent serial TEE examination, CRP level did not signif-
icantly change in these patients. The small sample size and
a difference in intensity of anticoagulation possibly explain
the lack of relationship between serial changes in CRP and
LA thrombus.
Limitations
First, this was a single-center retrospective study per-
formed in a relatively small number of patients. Second,
antithrombotic therapies were not randomized. The
formation of LA thrombus is critically dependent upon
anticoagulation status and anticoagulation duration. Third,
incidence of LA thrombus in patients with recent embolic
events may be underestimated because LA thrombus had
already been embolized and thus disappeared. Fourth,
[123
lthough LA thrombus was related to high CRP level, causal
elationship between prothrombotic state and inﬂammation
s unclear. In addition, although we found a cut-off CRP
alue for identifying LA thrombus, inﬂammation is not the
nly predictor of LA thrombus. Therefore, a cut-off CRP
alue may not be used for predicting LA thrombus but for
xcluding LA thrombus. Finally, it is unknown whether our
resent results can be applicable to all patients with AF.
onclusion
ystemic inﬂammation is related to LA thrombus formation
n patients with non-rheumatic AF. Our results indicate that
resence of systemic inﬂammation as evident by high CRP
evel may help stratify high-risk patients for LA thrombus
ormation and possibly stroke and peripheral embolism in
on-rheumatic AF.
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